How to read FDA’s Orange Book

An AB rating gets read as a verdict: this generic is the same drug. It’s narrower than that. The Orange Book’s therapeutic equivalence rating is FDA’s determination that a specific product can be substituted for a specific reference listed drug, under specific conditions — not a general statement that every drug sharing an active ingredient is interchangeable with every other. Reading the Orange Book for what it actually certifies, rather than what the two-letter code implies, matters most exactly when a generic substitution or a patent challenge is on the table.

What actually lands on the list

FDA doesn’t independently investigate what patents cover an approved drug. The information in the Orange Book’s patent and exclusivity addendum comes from the NDA holder, who submits it under 21 CFR 314.53 as part of approval and can update it afterward. A patent the NDA holder never submits doesn’t appear, however real it is; a listed patent means the applicant has certified it covers the drug, not that FDA has independently validated it. Therapeutic equivalence ratings work differently — those are FDA’s own evaluations, built primarily around bioequivalence data submitted for ANDAs filed under FD&C Act Section 505(j). A 2022 law narrowed how far that extends into the hybrid 505(b)(2) pathway, requiring FDA to evaluate only certain 505(b)(2) parenteral, ophthalmic, and otic products for an A rating; most 505(b)(2) products still don’t get routine TE evaluations at all. How to read a 505(b)(2) application covers that pathway in more depth.

What the rating does, and doesn’t, promise

An AB rating means FDA considers a specific generic product interchangeable with a specific reference listed drug for prescribing and dispensing purposes — not that every drug with a similar name or the same active ingredient is interchangeable with it. The rating can also move. If new information raises a question about the data FDA relied on when it rated a product, FDA can reclassify it from an A code to a B code, and the product loses its substitutable status until that’s resolved. Reading a TE code as permanent, or as applying beyond the specific reference drug it was rated against, is where the two-letter shorthand stops matching what FDA actually determined.

None of this requires tracking litigation strategy or memorizing exclusivity rules — the forfeiture conditions on 180-day exclusivity alone are detailed enough to warrant actual counsel rather than a shortcut. What’s worth carrying day to day is narrower: a TE code is a rating against one reference drug, not a category, and a listed patent is a certification FDA accepted, not one it independently verified.